Hims & Hers Health stock climbs as Novo Nordisk partnership boosts branded GLP-1 therapies outlook

Traders Union
All News
Financial News
Hims & Hers Health up 3.08% today

Highlights

Hims & Hers finalized a deal granting access to branded GLP-1 weight-loss drugs Wegovy and Ozempic, positioning for subscriber growth as compounded products are withdrawn.
First-quarter revenue increased 4% to $608.1 million despite a net loss of $92.1 million, driven in part by $33 million in restructuring charges; management raised full-year revenue guidance.
HIMS trades with short- to mid-term bullish momentum but near overbought territory, with a baseline price range of $27.50 to $32.00 and a higher likelihood of sideways or pullback action.

Expanded GLP-1 access and revenue guidance raise subscriber growth hopes

Hims & Hers Health recently reported first-quarter revenue growth of 4% to $608.1 million, accompanied by a net loss of $92.1 million as the company incurred $33 million in restructuring charges. The most significant development is a finalized agreement with Novo Nordisk, dated March 9, 2026, which allows Hims & Hers to distribute branded GLP-1 weight-loss medications Wegovy and Ozempic after earlier regulatory pressures and the withdrawal of compounded products. This partnership enhances access to in-demand therapies and supports continued subscriber growth, while management’s raised full-year revenue guidance further demonstrates confidence in ongoing business expansion.

Bullish momentum meets overbought risks as price holds firm

Technical analysis shows $29.14 trading decisively above the MA-20 at $27.59 and MA-50 at $23.49, but still capped by the MA-200 at $36.57. The Ichimoku Kijun level on the daily chart sits at $25.41, marking immediate support. MACD and ADX on D1 confirm robust bullish momentum, while RSI at 60.10 reflects ongoing buyer strength. However, elevated BBP highlights strong buyer dominance bordering on overbought, CCI is high at 76.15, and Stoch RSI though now neutral, flagged overbought conditions on higher timeframes. The trading session started with a moderate gap up and price remains in the upper third of today’s $28.63–$30.39 range, suggesting moderate to high intraday volatility and some divergence between trend strength and oscillator readings.

Limited breakout odds as indicators signal consolidation in trading range

In the short term, HIMS is expected to fluctuate within a typical volatility band of $27.50 to $32.00, reflecting prevailing market dynamics. With only one of four weekly indicators supporting further upside, the likelihood of a breakout above $32.00 is below 20%. The base scenario points to consolidation or sideways action within this corridor. A sustained push above $32.00 would require renewed buyer momentum, while a drop below $27.50 could confirm a deeper pullback and test lower support levels.

Viktoras Karapetjanc, analyst at Traders Union, sees Hims & Hers Health in a strong recovery phase after securing a key partnership with Novo Nordisk. He believes the new access to branded GLP-1 medications and raised revenue guidance are positive signals that outweigh near-term losses. Constructive technicals and resilient subscriber growth add to the upbeat outlook, with consolidation likely above $27.50 while market digests recent gains. In his words: "The Novo Nordisk deal affirms management's ability to navigate regulatory challenges and positions HIMS for further upside as demand for GLP-1 offerings accelerates."

Earlier, analysts noted that Hims & Hers Health was likely to consolidate as mixed technical signals and evolving business initiatives limited prospects for a decisive move. The latest earnings results, finalized Novo Nordisk partnership, and persistent overbought readings reinforce continued sideways action, with traders advised to monitor for volatility spikes or a catalyst-driven test of the $32.00 resistance in the near term.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.